Chemoimmunotherapy for Glioblastoma
Trial Summary
What is the purpose of this trial?
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in treating recurrent glioblastoma and to characterize the effect of this treatment on the participants tumor and immune system..
Research Team
Donald Miller, MD
Principal Investigator
University of Louisville/James Graham Brown Cancer Ctr.
Eligibility Criteria
This trial is for adults with confirmed glioblastoma, limited to the brain's upper part, who have completed standard chemoradiation. They must have adequate blood counts and organ function, no more than three prior treatments for high-grade glioma, and be able to consent. Women of childbearing age must test negative for pregnancy and use birth control; men also need contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants receive one cycle of Temozolomide and Pembrolizumab prior to tumor removal
Post-surgical Treatment
Participants receive three weekly cycles of Temozolomide and Pembrolizumab until progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Pembrolizumab
- Temozolomide
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Louisville
Lead Sponsor